247 related articles for article (PubMed ID: 36308322)
1. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
Le Terrier C; Nordmann P; Poirel L
J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
[TBL] [Abstract][Full Text] [Related]
2. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Le Terrier C; Freire S; Nordmann P; Poirel L
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
[TBL] [Abstract][Full Text] [Related]
3. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
[TBL] [Abstract][Full Text] [Related]
4. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
[TBL] [Abstract][Full Text] [Related]
5. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.
Le Terrier C; Nordmann P; Sadek M; Poirel L
J Antimicrob Chemother; 2023 May; 78(5):1191-1194. PubMed ID: 36921067
[TBL] [Abstract][Full Text] [Related]
7. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Le Terrier C; Nordmann P; Freret C; Seigneur M; Poirel L
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0033923. PubMed ID: 37255469
[TBL] [Abstract][Full Text] [Related]
8. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
9.
Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
[TBL] [Abstract][Full Text] [Related]
10.
Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
[TBL] [Abstract][Full Text] [Related]
11.
Karlowsky JA; Kazmierczak KM; de Jonge BLM; Hackel MA; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630192
[TBL] [Abstract][Full Text] [Related]
12. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
Lee M; Abbey T; Biagi M; Wenzler E
Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
[TBL] [Abstract][Full Text] [Related]
14. New β-Lactam-β-Lactamase Inhibitor Combinations.
Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
[TBL] [Abstract][Full Text] [Related]
15.
Huang YS; Chen PY; Chou PC; Wang JT
Microbiol Spectr; 2023 Jun; 11(3):e0056923. PubMed ID: 37154758
[TBL] [Abstract][Full Text] [Related]
16. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
Livermore DM; Mushtaq S; Vickers A; Woodford N
Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
[TBL] [Abstract][Full Text] [Related]
17.
Santerre Henriksen A; Jeannot K; Oliver A; Perry JD; Pletz MW; Stefani S; Morrissey I; Longshaw C;
Microbiol Spectr; 2024 Apr; 12(4):e0383623. PubMed ID: 38483164
[TBL] [Abstract][Full Text] [Related]
18. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
[TBL] [Abstract][Full Text] [Related]
19.
Cervino I; Gonzalez D; Nastro M; Vega J; Reyes AP; Buriano G; Vay C; Famiglietti A; Rodriguez CH
J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34605763
[TBL] [Abstract][Full Text] [Related]
20. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
